GEN Magazine (Genetic Engineering and Biotechnology News) featured the microfluidics research of Dr. Aaron Wheeler on November 15, 2012.
Wheeler, Canada Research Chair of Bioanalytical Chemistry and an associate professor at the University of Toronto, has made an invention disclosure to MaRS Innovation; Kapplex is the start-up company created to commercialize his research.
Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt:…
Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery
BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.
Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca